Natera, Inc.
Clinical trials sponsored by Natera, Inc., explained in plain language.
Natera, Inc.
NTRA
NASDAQ
A genetic testing company specializing in prenatal and oncology diagnostics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Blood test could replace painful heart biopsies for transplant patients Results expected Feb 2027 (estimated)
- New blood test could spot genetic diseases before birth Results expected Apr 2027 (estimated)
- Blood test could replace colonoscopy for cancer screening? Results expected Jul 2027 (estimated)